Diplomat Pharmacy (NYSE:DPLO) Lowered to Market Perform at Raymond James

Share on StockTwits

Diplomat Pharmacy (NYSE:DPLO) was downgraded by research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Monday, The Fly reports.

A number of other equities research analysts have also recently commented on DPLO. Barclays cut Diplomat Pharmacy from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $7.00 to $3.00 in a research report on Wednesday, November 13th. Wells Fargo & Co increased their price target on Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a “market perform” rating in a research report on Tuesday, August 13th. ValuEngine lowered Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a report on Thursday. Zacks Investment Research lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Friday, November 15th. Finally, Deutsche Bank began coverage on Diplomat Pharmacy in a research report on Thursday, September 12th. They issued a “sell” rating and a $4.00 price objective for the company. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $8.69.

DPLO opened at $5.81 on Monday. The firm has a fifty day moving average price of $5.00 and a 200 day moving average price of $5.24. Diplomat Pharmacy has a 1 year low of $2.43 and a 1 year high of $16.35. The stock has a market cap of $441.41 million, a P/E ratio of 29.05 and a beta of 0.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.55 and a quick ratio of 0.36.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($2.15). The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a negative net margin of 12.47% and a negative return on equity of 12.15%. The business’s revenue was down 5.3% compared to the same quarter last year. Equities analysts expect that Diplomat Pharmacy will post -0.92 EPS for the current year.

A number of large investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in shares of Diplomat Pharmacy by 184.8% in the second quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after acquiring an additional 3,103 shares in the last quarter. KBC Group NV purchased a new position in Diplomat Pharmacy in the 2nd quarter valued at $46,000. Man Group plc purchased a new position in Diplomat Pharmacy in the 3rd quarter valued at $51,000. Bank of Montreal Can boosted its stake in Diplomat Pharmacy by 138.4% during the 2nd quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock worth $70,000 after purchasing an additional 6,644 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new stake in Diplomat Pharmacy during the 2nd quarter worth $77,000. Institutional investors own 84.14% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Trading based on a resistance level

The Fly

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bowling Portfolio Management LLC Has $822,000 Stake in Mastercard Inc
Bowling Portfolio Management LLC Has $822,000 Stake in Mastercard Inc
Chemung Financial Corp.  Shares Sold by Bowling Portfolio Management LLC
Chemung Financial Corp. Shares Sold by Bowling Portfolio Management LLC
Cisco Systems, Inc.  Shares Sold by Commerzbank Aktiengesellschaft FI
Cisco Systems, Inc. Shares Sold by Commerzbank Aktiengesellschaft FI
Bowling Portfolio Management LLC Has $810,000 Stake in Kennedy-Wilson Holdings Inc
Bowling Portfolio Management LLC Has $810,000 Stake in Kennedy-Wilson Holdings Inc
State of Alaska Department of Revenue Sells 1,055 Shares of Ferro Co.
State of Alaska Department of Revenue Sells 1,055 Shares of Ferro Co.
Central Garden & Pet Co  Shares Sold by State of Alaska Department of Revenue
Central Garden & Pet Co Shares Sold by State of Alaska Department of Revenue


© 2006-2020 Ticker Report